Nexalin Regains Nasdaq Bid Price Compliance Above $1.00 Over 21 Straight Days

Nexalin Technology received formal written communication from Nasdaq confirming that the enterprise has successfully resolved its minimum bid price deficiency.¹ The exchange distributed this regulatory confirmation on September 30, 2026.¹ To satisfy the listing benchmark, the company needed to keep its share valuation at or above the designated baseline of $1.00.¹ Trading records established that the common stock maintained closing values greater than the $1.00 mark across 21 consecutive market sessions.¹ That sustained pricing interval extended without interruption from August 31, 2026, through September 29, 2026.¹

The upward trajectory of the share valuation followed structural capital adjustments executed prior to the streak.² Nexalin achieved the prerequisite closing marks exceeding $1.00 subsequent to an earlier reverse split of its shares.² This operational adjustment helped lift equity prices back across the mandatory dollar barrier during daily trading.¹² The subsequent twenty-one session span ending September 29 provided the sustained duration Nasdaq required to verify price recovery.¹

The resolution of the pricing issue occurred alongside formal panel review proceedings concerning the company's exchange presence.³ On September 25, 2026, the Nasdaq Hearings Panel granted authorization for Nexalin to maintain its active equity listing.³ Reports indicate that the business satisfied the panel's mandated bid price expectation within mere days of the panel releasing its determination.¹³ That determination allowed Nexalin to avoid immediate removal while establishing concrete milestones for remaining on the market.³

Although the pricing criterion has been fulfilled, Nexalin remains subject to additional listing stipulations outlined by the panel.¹² The regulatory ruling obligates the corporation to demonstrate adherence to the exchange's balance sheet standards.² Specifically, Nexalin must prove compliance with the minimum stockholders' equity benchmark of $2.5 million.² The exchange panel established an explicit deadline of January 4, 2027, for the firm to document that equity balance.²

The continuing listing authorization functions under strict supervisory oversight by exchange regulators throughout the provisional timeline.¹³ Under these instructions, Nexalin must provide immediate notification to the Nasdaq Hearings Panel regarding any major developments.³ This reporting mandate covers any significant events arising during the exception window that could influence the firm's standing on the exchange.³ At the same time, the panel has retained full authority to revisit and reconsider the terms of the exception it granted.¹

Corporate leadership expressed satisfaction with the administrative progress while recognizing the hurdles ahead.³ Chief Executive Officer Mark White declared that Nexalin was pleased with reaching the bid price standard and welcomed the panel's verdict.³ Nevertheless, the enterprise highlighted several forward-looking risks that could affect its corporate trajectory.³ Among these registered vulnerabilities is whether the company can successfully obtain capital financing or finalize transactions needed to meet the stockholders' equity condition.³

Nexalin's underlying business centers on medical instrumentation designed for therapeutic brain stimulation.¹ The company creates non-invasive neurostimulation medical devices that cannot be detected by the human body during use.¹ Its product line includes a Gen-2 15 milliamp neurostimulation unit targeted at international clinical healthcare sectors.² That specific generation of apparatus has secured formal regulatory clearances across China, Brazil, Oman, and Israel.²

Beyond its cleared international inventory, the organization is advancing research programs within the United States.¹² Nexalin is actively running a pivotal clinical trial titled HALO Clarity directed at the treatment of insomnia in American patients.² Alongside this clinical testing, the company is seeking marketing clearance from the United States Food and Drug Administration.¹ This ongoing federal submission process focuses specifically on securing clearance for its DIFS therapeutic technology.¹

Commercialization outside the domestic market recently expanded through cross-border trade arrangements.¹ The company entered into an agreement for distribution covering Brazil along with six additional Latin American jurisdictions.¹ Assessments suggest that while existing authorization in Brazil provides immediate market access there, entering the other six contracted nations necessitates obtaining separate local clearances.¹² Nexalin specifically cited this requirement for local permits outside Brazil as an operational risk factor in executing its regional expansion.²

The coming months will test Nexalin's capacity to balance operational milestones against exchange solvency rules.²³ Clearing the 21-day pricing bar removed the immediate risk of delisting related to its sub-dollar valuation.¹ However, meeting the January 4, 2027 deadline requires amassing at least $2.5 million in equity amidst uncertain financing conditions.²³ With the panel monitoring significant corporate events and retaining discretion to revise terms, the company must execute its plans under ongoing scrutiny.¹³